High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify ANCA-associated vasculitis (AAV) patients with high disease activity — and those at risk of a poor prognosis — a new study suggests. The researchers defined two cut-off values of syndecan-1…
Syndecan-1 levels may help ID AAV patients at risk of poor prognosis
The U.S. Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV). Developed by AstraZeneca, Fasenra was already approved in more than 80 countries, including the U.S., as an add-on treatment…
Rituximab may be associated with a higher risk of serious adverse events, particularly infections, in people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Time to first serious adverse event, as well as to second and multiple serious adverse events, is significantly shorter for patients treated with rituximab…
Tavneos (avacopan) effectively induces disease remission in adults with ANCA-associated vasculitis (AAV) and diffuse alveolar hemorrhage (DAH), that is, bleeding from the small blood vessels in the lungs, according to a real-world study in the U.S. The therapy also let all patients reduce their dose of glucocorticoids, a…
A diagnosis of ANCA vasculitis can drastically change our world and our priorities. We may have to adjust many aspects of our life, but do we have to change our hopes and dreams? After my diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), a type of ANCA…
ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG), or low blood levels of antibodies that help fight off infections, than people with other autoimmune conditions. That’s according to a real-world study in China that also found that higher…
Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA), according to a single-center study in Iran. While the safety profiles of the two therapies were comparable, treatment with rituximab was more effective, the study found. Specifically, about 90% of…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that predict patient outcomes better than classifying patients according to granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two AAV subtypes. The new disease clusters, identified with advanced artificial intelligence (AI)…
Nearly one year of treatment with rituximab was superior to traditional immunosuppressive medications at helping people with ANCA-associated vasculitis (AAV) achieve remission after a severe relapse, an analysis of data from a multicenter study in Japan has found. Such superiority was not observed at six months of treatment,…
The combination antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) may help prevent serious infections for people with granulomatosis with polyangiitis (GPA) who are taking the immunosuppressant rituximab, a study of U.S. data shows. Preventive treatment, or prophylaxis, with TMP-SMX in people with this common type of ANCA-associated vasculitis (AAV) tended to…
Recent Posts
- Chronic lung condition doubles infection risk in AAV patients: Study
- I often can’t breathe automatically due to lung issues and AAV
- New kidney risk score shows strong predictive power in AAV study
- Half of adults with AAV have interstitial lung disease at diagnosis, study finds
- Let’s do away with pity parties and start practicing self-compassion